• Waters partnered with Labcorp to expand access to the FDA-approved BD Onclarity HPV Assay through Labcorp's nationwide network beginning in late 2026.
• Labcorp intends to offer clinician-collected and self-collected screening options in clinics, patient service centers and at home.
• Its network serves more than 850,000 physicians and healthcare providers, with more than 2,200 patient service centers.
• The assay is the only FDA-approved HPV test supporting all ASCCP Enduring Risk-Based Management Guidelines through comprehensive extended genotyping.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Waters Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610230800PR_NEWS_USPR_____NY79551) on October 23, 2026, and is solely responsible for the information contained therein.